The estimated Net Worth of Peter N Reikes is at least $1.74 Milion dollars as of 15 October 2021. Mr. Reikes owns over 1,777 units of Ionis Pharmaceuticals Inc stock worth over $604,862 and over the last 6 years he sold IONS stock worth over $0. In addition, he makes $1,134,620 as Independent Director at Ionis Pharmaceuticals Inc.
Sign up
Mr. Reikes IONS stock SEC Form 4 insiders trading
Peter has made over 5 trades of the Ionis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,777 units of IONS stock worth $75,576 on 15 October 2021.
The largest trade he's ever made was exercising 7,111 units of Ionis Pharmaceuticals Inc stock on 15 July 2021 worth over $302,431. On average, Peter trades about 1,580 units every 81 days since 2018. As of 15 October 2021 he still owns at least 14,222 units of Ionis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Reikes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Reikes biography
Peter N. Reikes is Independent Director of the Company. Mr. Reikes is a Vice Chairman in the Investment Banking Division at Stifel, Nicolaus & Company, Inc., which he joined in late 2010. Over the course of his extensive career in investment banking, Mr. Reikes has completed a wide range of financing and merger and acquisition transactions for companies in the life sciences, medical technology and healthcare services sectors. Prior to joining Stifel, Nicolaus, he spent 11 years at Cowen and Company, LLC, where he was Vice Chairman and Head of Healthcare Investment Banking, and over 14 years at PaineWebber Incorporated, where he was a Managing Director and Head of Healthcare Investment Banking and began his career in 1985. Mr. Reikes is also a director of the Heart & Soul Foundation, an organization that supports a range of community service programs in the greater New York City area. Mr. Reikes is a former director of Ricerca Biosciences, LLC, Biocompatibles, Ltd., and the affiliated partnership boards of Alkermes, Inc., Cephalon, Inc., Gensia, Inc., Genzyme Corporation and Repligen Corporation, as well as the Institute for Quality Improvement of the Accreditation Association for Ambulatory Health Care. Mr. Reikes received his B.A. in Economics from the University of California at Los Angeles and his M.B.A. in Finance from The Wharton School at the University of Pennsylvania. The Board believes Mr. Reikes is uniquely suited to serve on the Board primarily because of his extensive experience in finance and strategic transactions for companies in the life sciences, medical technology and healthcare services industries.
What is the salary of Peter Reikes?
As the Independent Director of Ionis Pharmaceuticals Inc, the total compensation of Peter Reikes at Ionis Pharmaceuticals Inc is $1,134,620. There are 16 executives at Ionis Pharmaceuticals Inc getting paid more, with Stanley Crooke having the highest compensation of $9,598,830.
How old is Peter Reikes?
Peter Reikes is 59, he's been the Independent Director of Ionis Pharmaceuticals Inc since 2018. There are 17 older and 8 younger executives at Ionis Pharmaceuticals Inc. The oldest executive at Ionis Pharmaceuticals Inc is Breaux Castleman, 79, who is the Independent Director.
What's Peter Reikes's mailing address?
Peter's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Ionis Pharmaceuticals Inc
Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall oraz Michael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.
What does Ionis Pharmaceuticals Inc do?
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
What does Ionis Pharmaceuticals Inc's logo look like?
Complete history of Mr. Reikes stock trades at Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc executives and stock owners
Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stanley Crooke,
Executive Chairman of the Board of Directors -
Brett Monia,
Chief Executive Officer, Director -
Richard Geary,
Senior Vice President - Development -
Elizabeth Hougen,
Senior Vice President, Finance and Chief Financial Officer -
Patrick O'Neil,
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary -
Joan Herman,
Director -
B. Lynne Parshall,
Director -
Dr. Brett P. Monia Ph.D.,
Founder, CEO & Director -
Dr. Stanley T. Crooke,
Scientific Advisor -
Joseph Klein,
Independent Director -
Joseph Wender,
Independent Director -
Spencer Berthelsen,
Independent Director -
Breaux Castleman,
Independent Director -
Frederick Muto,
Independent Director -
Michael Hayden,
Independent Director -
Joseph Loscalzo,
Independent Director -
Peter Reikes,
Independent Director -
B. Lynne Parshall Esq., J.D.,
Sr. Strategic Advisor & Director -
C. Frank Bennett,
Chief Scientific Officer -
Dr. Richard S. Geary,
Exec. VP & Chief Devel. Officer -
Elizabeth L. Hougen,
Exec. VP of Fin. & CFO -
Patrick R. O'Neil Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Eric E. Swayze Ph.D.,
Exec. VP of Research -
D. Wade Walke,
Investor Relations -
Onaiza Cadoret-Manier,
Chief Corporate Development and Commercial Officer -
Eric Swayze,
Senior Vice President - Research -
Dr. C. Frank Bennett,
Exec. VP & Chief Scientific Officer -
Darren Gonzales,
Chief Accounting Officer & Sr. VP -
Joel Edwards,
VP of Corp. Operations -
Damien Mc Devitt,
Chief Business Officer -
Sarah Boyce,
Chief Business Officer -
Joseph Baroldi,
EVP, Chief Business Officer -
Kyle Jenne,
EVP, Chf GL Pdt Str Ofcr -
Allene M. Diaz,
Director -
Brian Birchler,
EVP, Corp and Development Ops -
Eugene Schneider,
EVP, Chf Clinical Develop Ofcr -
Michael J. Yang,
Director